Traws Pharma (TRAW) investor relations material

Opening remarks and agenda

• Meeting commenced with a welcome and introduction of board members and officers, including the Chairman, CEO, and CFO.

• Virtual format adopted, with instructions for shareholder participation and voting.

• Record date for voting eligibility set as May 18, 2026, with 15,150,669 shares outstanding.

• Quorum established with approximately 8.5 million shares represented (56% of eligible shares).

Shareholder proposals

• Proposal 1: Election of seven directors to serve until the next annual meeting.

• Proposal 2: Amendment to the 2021 Incentive Compensation Plan, increasing available shares by 2 million and making administrative changes.

• Proposal 3: Ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2026.

• Proposal 4: Approval of issuance of shares upon exercise of Series B and Series C warrants.

• Proposal 5: Authorization to adjourn the annual meeting if necessary.

Overview of voting outcomes

• All director nominees elected.

• Amendment to the 2021 Incentive Compensation Plan approved.

• Ratification of KPMG LLP as auditor approved.

• Issuance of shares upon exercise of Series B and C warrants approved.

• Adjournment proposal approved but not enacted as all other proposals passed.

• Final voting results to be filed with the SEC on Form 8-K within four business days.